ArticleDermatologic therapy2021
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
Article in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports.Dermatology reports · 2024Article
- COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation.Life (Basel, Switzerland) · 2024Article
- Long-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?Dermatology practical & conceptual · 2023Article
- Treating asthma in the time of COVID.The Journal of allergy and clinical immunology · 2023Article
- The effect of COVID-19 on patients recieving omalizumab treatment.Revue francaise d'allergologie (2009) · 2023Article
- Sleep Quality as a Predictor of Quality-of-Life and Emotional Status Impairment in Patients with Chronic Spontaneous Urticaria: A Cross-Sectional Study.International journal of environmental research and public health · 2023Article
- Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.Journal of cosmetic dermatology · 2023Article
- The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.Revue francaise d'allergologie (2009) · 2022Article
- Colchicine in Managing Skin Conditions: A Systematic Review.Pharmaceutics · 2022Review
- COVID-19 Disease Leading to Chronic Spontaneous Urticaria Exacerbation: A Romanian Retrospective Study.Healthcare (Basel, Switzerland) · 2021Article
- Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.Journal of inflammation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.